CARs: Driving T-cell specificity to enhance anti-tumor immunity

Frontiers in Bioscience - Scholar

Volumn 4 S, Issue 2, 2012, Pages 520-531

  Kebriaei, Partow ^a   Kelly, Susan S ^a   Manuri, Pallavi ^a   Jena, Bipulendu ^a   Jackson, Rineka ^a   Shpall, Elizabeth ^a   Champlin, Richard ^a   Cooper, Laurence J N ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

Cancer therapeutics; Cellular therapy; Chimeric antigen receptor; Lymphoid malignancies; Review; T cell therapy

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; CD137 LIGAND; CD3 ANTIGEN; CHIMERIC ANTIGEN RECEPTOR; CYCLOPHOSPHAMIDE; FLUDARABINE; INTERLEUKIN 2; INTERLEUKIN 7; LYMPHOCYTE ANTIGEN RECEPTOR; PLASMID DNA; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; T LYMPHOCYTE RECEPTOR; TRANSFORMING GROWTH FACTOR BETA; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ADAPTIVE IMMUNITY; ANTIGEN STRUCTURE; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CELL MIGRATION; CELL SPECIFICITY; CELL SURVIVAL; CELL THERAPY; CLINICAL TRIAL (TOPIC); DNA MODIFICATION; FOLLICULAR LYMPHOMA; HUMAN; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; PROTEIN EXPRESSION; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TUMOR ASSOCIATED LEUKOCYTE; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT;

EID: 84883660283     PISSN: 19450516     EISSN: 19450524     Source Type: Journal    
DOI: 10.2741/s282     Document Type: Article

References (99)

1. H. J. Kolb: Graft-versus-leukemia effects of transplantation and donor lymphocytes. Blood, 112(12), 4371-83 (2008)
2. J. O. Cullis, Y. Z. Jiang, A. P. Schwarer, T. P. Hughes, A. J. Barrett and J. M. Goldman: Donor leukocyte infusions for chronic myeloid leukemia in relapse after allogeneic bone marrow transplantation. Blood, 79(5), 1379-81 (1992)
3. W. R. Drobyski, C. A. Keever, M. S. Roth, S. Koethe, G. Hanson, P. McFadden, J. L. Gottschall, R. C. Ash, P. van Tuinen, M. M. Horowitz and et al.: Salvage immunotherapy using donor leukocyte infusions as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation: efficacy and toxicity of a defined T-cell dose. Blood, 82(8), 2310-8 (1993) (Pubitemid 23304253)
4. A. Ferster, W. Bujan, T. Mouraux, C. Devalck, P. Heimann and E. Sariban: Complete remission following donor leukocyte infusion in ALL relapsing after haploidentical bone marrow transplantation. Bone Marrow Transplant, 14(2), 331-2 (1994) (Pubitemid 24262562)
5. H. J. Kolb, J. Mittermuller, C. Clemm, E. Holler, G. Ledderose, G. Brehm, M. Heim and W. Wilmanns: Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood, 76(12), 2462-5 (1990)
6. H. M. Lokhorst, A. Schattenberg, J. J. Cornelissen, L. L. Thomas and L. F. Verdonck: Donor leukocyte infusions are effective in relapsed multiple myeloma after allogeneic bone marrow transplantation. Blood, 90(10), 4206-11 (1997) (Pubitemid 27484078)
7. A. R. Pati, K. Godder, L. Lamb, A. Gee and P. J. Henslee-Downey: Immunotherapy with donor leukocyte infusions for patients with relapsed acute myeloid leukemia following partially mismatched related donor bone marrow transplantation. Bone Marrow Transplant, 15(6), 979-81 (1995)
8. L. Vago, S. K. Perna, M. Zanussi, B. Mazzi, C. Barlassina, M. T. Stanghellini, N. F. Perrelli, C. Cosentino, F. Torri, A. Angius, B. Forno, M. Casucci, M. Bernardi, J. Peccatori, C. Corti, A. Bondanza, M. Ferrari, S. Rossini, M. G. Roncarolo, C. Bordignon, C. Bonini, F. Ciceri and K. Fleischhauer: Loss of mismatched HLA in leukemia after stem-cell transplantation. N Engl J Med, 361(5), 478-88 (2009)
9. W. Zou: Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat Rev Cancer, 5(4), 263-74 (2005) (Pubitemid 40488632)
10. Z. Eshhar, T. Waks, G. Gross and D. G. Schindler: Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibodybinding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors. Proc Natl Acad Sci U S A, 90(2), 720-4 (1993) (Pubitemid 23028937)
11. S. A. Rosenberg, N. P. Restifo, J. C. Yang, R. A. Morgan and M. E. Dudley: Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat Rev Cancer, 8(4), 299-308 (2008) (Pubitemid 351430867)
12. K. S. Kahlon, C. Brown, L. J. Cooper, A. Raubitschek, S. J. Forman and M. C. Jensen: Specific recognition and killing of glioblastoma multiforme by interleukin 13-zetakine redirected cytolytic T cells. Cancer Res, 64(24), 9160-6 (2004) (Pubitemid 39665531)
13. C. Imai, K. Mihara, M. Andreansky, I. C. Nicholson, C. H. Pui, T. L. Geiger and D. Campana: Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia. Leukemia, 18(4), 676-84 (2004) (Pubitemid 38500185)
14. Y. Zhao, Q. J. Wang, S. Yang, J. N. Kochenderfer, Z. Zheng, X. Zhong, M. Sadelain, Z. Eshhar, S. A. Rosenberg and R. A. Morgan: A herceptin-based chimeric antigen receptor with modified signaling domains leads to enhanced survival of transduced T lymphocytes and antitumor activity. J Immunol, 183(9), 5563-74 (2009)
15. F. Letourneur and R. D. Klausner: T-cell and basophil activation through the cytoplasmic tail of T-cell-receptor zeta family proteins. Proc Natl Acad Sci U S A, 88(20), 8905-9 (1991) (Pubitemid 21915538)
16. C. O. Yun, K. F. Nolan, E. J. Beecham, R. A. Reisfeld and R. P. Junghans: Targeting of T lymphocytes to melanoma cells through chimeric anti-GD3 immunoglobulin T-cell receptors. Neoplasia, 2(5), 449-59 (2000) (Pubitemid 32044791)
17. H. Abken, A. Hombach and C. Heuser: Immune response manipulation: recombinant immunoreceptors endow T-cells with predefined specificity. Curr Pharm Des, 9(24), 1992-2001 (2003) (Pubitemid 37010105)
18. J. Wang, M. Jensen, Y. Lin, X. Sui, E. Chen, C. G. Lindgren, B. Till, A. Raubitschek, S. J. Forman, X. Qian, S. James, P. Greenberg, S. Riddell and O. W. Press: Optimizing adoptive polyclonal T cell immunotherapy of lymphomas, using a chimeric T cell receptor possessing CD28 and CD137 costimulatory domains. Hum Gene Ther, 18(8), 712-25 (2007) (Pubitemid 47378068)
19. E. Yvon, M. Del Vecchio, B. Savoldo, V. Hoyos, A. Dutour, A. Anichini, G. Dotti and M. K. Brenner: Immunotherapy of metastatic melanoma using genetically engineered GD2-specific T cells. Clin Cancer Res, 15(18), 5852-60 (2009)
20. M. Sadelain, R. Brentjens and I. Riviere: The promise and potential pitfalls of chimeric antigen receptors. Curr Opin Immunol, 21(2), 215-23 (2009)
21. C. M. Kowolik, M. S. Topp, S. Gonzalez, T. Pfeiffer, S. Olivares, N. Gonzalez, D. D. Smith, S. J. Forman, M. C. Jensen and L. J. Cooper: CD28 costimulation provided through a CD19-specific chimeric antigen receptor enhances in vivo persistence and antitumor efficacy of adoptively transferred T cells. Cancer Res, 66(22), 10995-1004 (2006) (Pubitemid 44876999)
22. M. C. Jensen, L. Popplewell, L. J. Cooper, D. DiGiusto, M. Kalos, J. R. Ostberg and S. J. Forman: Antitransgene rejection responses contribute to attenuated persistence of adoptively transferred CD20/CD19-specific chimeric antigen receptor redirected T cells in humans. Biol Blood Marrow Transplant, 16(9), 1245-56 (2010)
23. B. G. Till, M. C. Jensen, J. Wang, E. Y. Chen, B. L. Wood, H. A. Greisman, X. Qian, S. E. James, A. Raubitschek, S. J. Forman, A. K. Gopal, J. M. Pagel, C. G. Lindgren, P. D. Greenberg, S. R. Riddell and O. W. Press: Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells. Blood, 112(6), 2261-71 (2008)
24. J. R. Park, D. L. Digiusto, M. Slovak, C. Wright, A. Naranjo, J. Wagner, H. B. Meechoovet, C. Bautista, W. C. Chang, J. R. Ostberg and M. C. Jensen: Adoptive transfer of chimeric antigen receptor re-directed cytolytic T lymphocyte clones in patients with neuroblastoma. Mol Ther, 15(4), 825-33 (2007) (Pubitemid 46432004)
25. M. A. Pule, B. Savoldo, G. D. Myers, C. Rossig, H. V. Russell, G. Dotti, M. H. Huls, E. Liu, A. P. Gee, Z. Mei, E. Yvon, H. L. Weiss, H. Liu, C. M. Rooney, H. E. Heslop and M. K. Brenner: Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma. Nat Med, 14(11), 1264-70 (2008)
26. H. M. Finney, A. D. Lawson, C. R. Bebbington and A. N. Weir: Chimeric receptors providing both primary and costimulatory signaling in T cells from a single gene product. J Immunol, 161(6), 2791-7 (1998) (Pubitemid 28425698)
27. A. Hombach, A. Wieczarkowiecz, T. Marquardt, C. Heuser, L. Usai, C. Pohl, B. Seliger and H. Abken: Tumorspecific T cell activation by recombinant immunoreceptors: CD3 zeta signaling and CD28 costimulation are simultaneously required for efficient IL-2 secretion and can be integrated into one combined CD28/CD3 zeta signaling receptor molecule. J Immunol, 167(11), 6123-31 (2001) (Pubitemid 33081538)
28. J. N. Kochenderfer, W. H. Wilson, J. E. Janik, M. E. Dudley, M. Stetler-Stevenson, S. A. Feldman, I. Maric, M. Raffeld, D. A. Nathan, B. J. Lanier, R. A. Morgan and S. A. Rosenberg: Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically-engineered to recognize CD19. Blood (2010)
29. R. A. Morgan, J. C. Yang, M. Kitano, M. E. Dudley, C. M. Laurencot and S. A. Rosenberg: Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther, 18(4), 843-51 (2010)
30. C. R. Pameijer, A. Navanjo, B. Meechoovet, J. R. Wagner, B. Aguilar, C. L. Wright, W. C. Chang, C. E. Brown and M. C. Jensen: Conversion of a tumor-binding peptide identified by phage display to a functional chimeric T cell antigen receptor. Cancer Gene Ther, 14(1), 91-7 (2007) (Pubitemid 44952238)
31. R. A. Willemsen, R. Debets, E. Hart, H. R. Hoogenboom, R. L. Bolhuis and P. Chames: A phage display selected fab fragment with MHC class I-restricted specificity for MAGEA1 allows for retargeting of primary human T lymphocytes. Gene Ther, 8(21), 1601-8 (2001) (Pubitemid 33085581)
32. M. Chmielewski, A. Hombach, C. Heuser, G. P. Adams and H. Abken: T cell activation by antibody-like immunoreceptors: increase in affinity of the single-chain fragment domain above threshold does not increase T cell activation against antigen-positive target cells but decreases selectivity. J Immunol, 173(12), 7647-53 (2004) (Pubitemid 39628207)
33. J. Vera, B. Savoldo, S. Vigouroux, E. Biagi, M. Pule, C. Rossig, J. Wu, H. E. Heslop, C. M. Rooney, M. K. Brenner and G. Dotti: T lymphocytes redirected against the kappa light chain of human immunoglobulin efficiently kill mature B lymphocyte-derived malignant cells. Blood, 108(12), 3890-7 (2006) (Pubitemid 44864573)
34. A. Hombach, C. Schneider, D. Sent, D. Koch, R. A. Willemsen, V. Diehl, W. Kruis, R. L. Bolhuis, C. Pohl and H. Abken: An entirely humanized CD3 zeta-chain signaling receptor that directs peripheral blood t cells to specific lysis of carcinoembryonic antigen-positive tumor cells. Int J Cancer, 88(1), 115-20 (2000)
35. C. H. June, B. R. Blazar and J. L. Riley: Engineering lymphocyte subsets: tools, trials and tribulations. Nat Rev Immunol, 9(10), 704-16 (2009)
36. B. Jena, G. Dotti and L. J. Cooper: Redirecting T-cell specificity by introducing a tumor-specific chimeric antigen receptor. Blood, 116(7), 1035-44 (2010)
37. S. A. Rosenberg, P. Aebersold, K. Cornetta, A. Kasid, R. A. Morgan, R. Moen, E. M. Karson, M. T. Lotze, J. C. Yang, S. L. Topalian and et al.: Gene transfer into humans-immunotherapy of patients with advanced melanoma, using tumor-infiltrating lymphocytes modified by retroviral gene transduction. N Engl J Med, 323(9), 570-8 (1990) (Pubitemid 20260084)
38. M. Rischer, S. Pscherer, S. Duwe, J. Vormoor, H. Jurgens and C. Rossig: Human gammadelta T cells as mediators of chimaeric-receptor redirected anti-tumour immunity. Br J Haematol, 126(4), 583-92 (2004) (Pubitemid 39093102)
39. F. Turatti, M. Figini, P. Alberti, R. A. Willemsen, S. Canevari and D. Mezzanzanica: Highly efficient redirected anti-tumor activity of human lymphocytes transduced with a completely human chimeric immune receptor. J Gene Med, 7(2), 158-70 (2005) (Pubitemid 40348020)
40. M. C. Milone, J. D. Fish, C. Carpenito, R. G. Carroll, G. K. Binder, D. Teachey, M. Samanta, M. Lakhal, B. Gloss, G. Danet-Desnoyers, D. Campana, J. L. Riley, S. A. Grupp and C. H. June: Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo. Mol Ther, 17(8), 1453-64 (2009)
41. L. Naldini, U. Blomer, P. Gallay, D. Ory, R. Mulligan, F. H. Gage, I. M. Verma and D. Trono: In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science, 272(5259), 263-7 (1996) (Pubitemid 26119138)
42. A. Varela-Rohena, C. Carpenito, E. E. Perez, M. Richardson, R. V. Parry, M. Milone, J. Scholler, X. Hao, A. Mexas, R. G. Carroll, C. H. June and J. L. Riley: Genetic engineering of T cells for adoptive immunotherapy. Immunol Res, 42(1-3), 166-81 (2008)
43. A. M. Geurts, Y. Yang, K. J. Clark, G. Liu, Z. Cui, A. J. Dupuy, J. B. Bell, D. A. Largaespada and P. B. Hackett: Gene transfer into genomes of human cells by the sleeping beauty transposon system. Mol Ther, 8(1), 108-17 (2003) (Pubitemid 36939302)
44. X. Huang, H. Guo, J. Kang, S. Choi, T. C. Zhou, S. Tammana, C. J. Lees, Z. Z. Li, M. Milone, B. L. Levine, J. Tolar, C. H. June, R. Scott McIvor, J. E. Wagner, B. R. Blazar and X. Zhou: Sleeping Beauty transposon-mediated engineering of human primary T cells for therapy of CD19+ lymphoid malignancies. Mol Ther, 16(3), 580-9 (2008) (Pubitemid 351314999)
45. M. C. Jensen, P. Clarke, G. Tan, C. Wright, W. Chung-Chang, T. N. Clark, F. Zhang, M. L. Slovak, A. M. Wu, S. J. Forman and A. Raubitschek: Human T lymphocyte genetic modification with naked DNA. Mol Ther, 1(1), 49-55 (2000)
46. L. J. Cooper, M. S. Topp, L. M. Serrano, S. Gonzalez, W. C. Chang, A. Naranjo, C. Wright, L. Popplewell, A. Raubitschek, S. J. Forman and M. C. Jensen: T-cell clones can be rendered specific for CD19: toward the selective augmentation of the graft-versus-B-lineage leukemia effect. Blood, 101(4), 1637-44 (2003) (Pubitemid 36182545)
47. H. Singh, P. R. Manuri, S. Olivares, N. Dara, M. J. Dawson, H. Huls, P. B. Hackett, D. B. Kohn, E. J. Shpall, R. E. Champlin and L. J. Cooper: Redirecting specificity of T-cell populations for CD19 using the Sleeping Beauty system. Cancer Res, 68(8), 2961-71 (2008) (Pubitemid 351556297)
48. X. Xue, X. Huang, S. E. Nodland, L. Mates, L. Ma, Z. Izsvak, Z. Ivics, T. W. LeBien, R. S. McIvor, J. E. Wagner and X. Zhou: Stable gene transfer and expression in cord blood-derived CD34+ hematopoietic stem and progenitor cells by a hyperactive Sleeping Beauty transposon system. Blood, 114(7), 1319-30 (2009)
49. P. V. Manuri, M. H. Wilson, S. N. Maiti, T. Mi, H. Singh, S. Olivares, M. J. Dawson, H. Huls, D. A. Lee, P. H. Rao, J. M. Kaminski, Y. Nakazawa, S. Gottschalk, P. Kebriaei, E. J. Shpall, R. E. Champlin and L. J. Cooper: piggyBac transposon/transposase system to generate CD19-specific T cells for the treatment of B-lineage malignancies. Hum Gene Ther, 21(4), 427-37 (2009)
50. Y. Nakazawa, L. E. Huye, G. Dotti, A. E. Foster, J. F. Vera, P. R. Manuri, C. H. June, C. M. Rooney and M. H. Wilson: Optimization of the PiggyBac transposon system for the sustained genetic modification of human T lymphocytes. J Immunother, 32(8), 826-36 (2009)
51. P. B. Hackett, S. C. Ekker, D. A. Largaespada and R. S. McIvor: Sleeping beauty transposon-mediated gene therapy for prolonged expression. Adv Genet, 54, 189-232 (2005) (Pubitemid 43591151)
52. Z. Ivics, P. B. Hackett, R. H. Plasterk and Z. Izsvak: Molecular reconstruction of Sleeping Beauty, a Tc1-like transposon from fish, and its transposition in human cells. Cell, 91(4), 501-10 (1997) (Pubitemid 27508239)
53. Z. Izsvak, M. K. Chuah, T. Vandendriessche and Z. Ivics: Efficient stable gene transfer into human cells by the Sleeping Beauty transposon vectors. Methods, 49(3), 287-97 (2009)
54. P. B. Hackett, D. A. Largaespada and L. J. Cooper: A transposon and transposase system for human application. Mol Ther, 18(4), 674-83 (2010)
55. Z. Izsvak, P. B. Hackett, L. J. Cooper and Z. Ivics: Translating Sleeping Beauty transposition into cellular therapies: victories and challenges. Bioessays, 32(9), 756-67 (2010)
56. C. Rossig, C. M. Bollard, J. G. Nuchtern, C. M. Rooney and M. K. Brenner: Epstein-Barr virus-specific human T lymphocytes expressing antitumor chimeric T-cell receptors: potential for improved immunotherapy. Blood, 99(6), 2009-16 (2002) (Pubitemid 34525482)
57. L. J. Cooper, Z. Al-Kadhimi, L. M. Serrano, T. Pfeiffer, S. Olivares, A. Castro, W. C. Chang, S. Gonzalez, D. Smith, S. J. Forman and M. C. Jensen: Enhanced antilymphoma efficacy of CD19-redirected influenza MP1-specific CTLs by cotransfer of T cells modified to present influenza MP1. Blood, 105(4), 1622-31 (2005) (Pubitemid 40223683)
58. M. T. Stephan, V. Ponomarev, R. J. Brentjens, A. H. Chang, K. V. Dobrenkov, G. Heller and M. Sadelain: T cell-encoded CD80 and 4-1BBL induce auto-and transcostimulation, resulting in potent tumor rejection. Nat Med, 13(12), 1440-9 (2007) (Pubitemid 350224246)
59. C. S. Hinrichs, Z. A. Borman, L. Cassard, L. Gattinoni, R. Spolski, Z. Yu, L. Sanchez-Perez, P. Muranski, S. J. Kern, C. Logun, D. C. Palmer, Y. Ji, R. N. Reger, W. J. Leonard, R. L. Danner, S. A. Rosenberg and N. P. Restifo: Adoptively transferred effector cells derived from naive rather than central memory CD8+ T cells mediate superior antitumor immunity. Proc Natl Acad Sci U S A, 106(41), 17469-74 (2009)
60. C. Berger, M. C. Jensen, P. M. Lansdorp, M. Gough, C. Elliott and S. R. Riddell: Adoptive transfer of effector CD8+ T cells derived from central memory cells establishes persistent T cell memory in primates. J Clin Invest, 118(1), 294-305 (2008)
61. C. Berger, M. Berger, D. Anderson and S. R. Riddell: A non-human primate model for analysis of safety, persistence, and function of adoptively transferred T cells. J Med Primatol (2010)
62. M. E. Dudley, J. C. Yang, R. Sherry, M. S. Hughes, R. Royal, U. Kammula, P. F. Robbins, J. Huang, D. E. Citrin, S. F. Leitman, J. Wunderlich, N. P. Restifo, A. Thomasian, S. G. Downey, F. O. Smith, J. Klapper, K. Morton, C. Laurencot, D. E. White and S. A. Rosenberg: Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J Clin Oncol, 26(32), 5233-9 (2008)
63. C. H. Lamers, S. Sleijfer, A. G. Vulto, W. H. Kruit, M. Kliffen, R. Debets, J. W. Gratama, G. Stoter and E. Oosterwijk: Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience. J Clin Oncol, 24(13), e20-2 (2006)
64. C. H. Lamers, R. Willemsen, P. van Elzakker, S. van Steenbergen- Langeveld, M. Broertjes, J. Oosterwijk-Wakka, E. Oosterwijk, S. Sleijfer, R. Debets and J. W. Gratama: Immune responses to transgene and retroviral vector in patients treated with ex vivo engineered T cells. Blood (2010)
65. M. H. Kershaw, J. A. Westwood, L. L. Parker, G. Wang, Z. Eshhar, S. A. Mavroukakis, D. E. White, J. R. Wunderlich, S. Canevari, L. Rogers-Freezer, C. C. Chen, J. C. Yang, S. A. Rosenberg and P. Hwu: A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer. Clin Cancer Res, 12(20 Pt 1), 6106-15 (2006) (Pubitemid 44703776)
66. S. O. P. R. Manuri, N. Dara, M. J. Dawson, H. Huls, D. A. Lee, E. J. Shpall, R. E. Champlin, L. J. N. Cooper: A Fully-Human Chimeric Antigen Receptor for Redirecting Specificity of T Cells to B-Lineage Tumors In: American Society for Blood and Marrow Transplantation, Tandem Meetings. San Diego, California (2008)
67. R. Carrio, C. E. Rolle and T. R. Malek: Non-redundant role for IL-7R signaling for the survival of CD8+ memory T cells. Eur J Immunol, 37(11), 3078-88 (2007) (Pubitemid 350131287)
68. D. J. Powell, Jr., M. E. Dudley, P. F. Robbins and S. A. Rosenberg: Transition of late-stage effector T cells to CD27+ CD28+ tumor-reactive effector memory T cells in humans after adoptive cell transfer therapy. Blood, 105(1), 241-50 (2005) (Pubitemid 40053089)
69. J. F. Vera, V. Hoyos, B. Savoldo, C. Quintarelli, G. M. Giordano Attianese, A. M. Leen, H. Liu, A. E. Foster, H. E. Heslop, C. M. Rooney, M. K. Brenner and G. Dotti: Genetic manipulation of tumor-specific cytotoxic T lymphocytes to restore responsiveness to IL-7. Mol Ther, 17(5), 880-8 (2009)
70. T. Sogo, M. Kawahara, K. Tsumoto, I. Kumagai, H. Ueda and T. Nagamune: Selective expansion of genetically modified T cells using an antibody/interleukin-2 receptor chimera. J Immunol Methods, 337(1), 16-23 (2008)
71. J. C. Markley and M. Sadelain: IL-7 and IL-21 are superior to IL-2 and IL-15 in promoting human T cellmediated rejection of systemic lymphoma in immunodeficient mice. Blood, 115(17), 3508-19 (2009)
72. K. Liu and S. A. Rosenberg: Transduction of an IL-2 gene into human melanoma-reactive lymphocytes results in their continued growth in the absence of exogenous IL-2 and maintenance of specific antitumor activity. J Immunol, 167(11), 6356-65 (2001) (Pubitemid 33081567)
73. C. Hsu, S. A. Jones, C. J. Cohen, Z. Zheng, K. Kerstann, J. Zhou, P. F. Robbins, P. D. Peng, X. Shen, T. J. Gomes, C. E. Dunbar, D. J. Munroe, C. Stewart, K. Cornetta, D. Wangsa, T. Ried, S. A. Rosenberg and R. A. Morgan: Cytokine-independent growth and clonal expansion of a primary human CD8+ T-cell clone following retroviral transduction with the IL-15 gene. Blood, 109(12), 5168-77 (2007) (Pubitemid 46890533)
74. V. Hoyos, B. Savoldo, C. Quintarelli, A. Mahendravada, M. Zhang, J. Vera, H. E. Heslop, C. M. Rooney, M. K. Brenner and G. Dotti: Engineering CD19-specific T lymphocytes with interleukin-15 and a suicide gene to enhance their anti-lymphoma/leukemia effects and safety. Leukemia, 24(6), 1160-70 (2010)
75. J. Rowley, A. Monie, C. F. Hung and T. C. Wu: Expression of IL-15RA or an IL-15/IL-15RA fusion on CD8+ T cells modifies adoptively transferred T-cell function in cis. Eur J Immunol, 39(2), 491-506 (2009)
76. B. Heemskerk, K. Liu, M. E. Dudley, L. A. Johnson, A. Kaiser, S. Downey, Z. Zheng, T. E. Shelton, K. Matsuda, P. F. Robbins, R. A. Morgan and S. A. Rosenberg: Adoptive cell therapy for patients with melanoma, using tumorinfiltrating lymphocytes genetically engineered to secrete interleukin-2. Hum Gene Ther, 19(5), 496-510 (2008) (Pubitemid 351748783)
77. C. M. Bollard, C. Rossig, M. J. Calonge, M. H. Huls, H. J. Wagner, J. Massague, M. K. Brenner, H. E. Heslop and C. M. Rooney: Adapting a transforming growth factor beta-related tumor protection strategy to enhance antitumor immunity. Blood, 99(9), 3179-87 (2002) (Pubitemid 34525296)
78. A. Loskog, V. Giandomenico, C. Rossig, M. Pule, G. Dotti and M. K. Brenner: Addition of the CD28 signaling domain to chimeric T-cell receptors enhances chimeric Tcell resistance to T regulatory cells. Leukemia, 20(10), 1819-28 (2006) (Pubitemid 44574993)
79. U. Palendira, R. Chinn, W. Raza, K. Piper, G. Pratt, L. Machado, A. Bell, N. Khan, A. D. Hislop, R. Steyn, A. B. Rickinson, C. D. Buckley and P. Moss: Selective accumulation of virus-specific CD8+ T cells with unique homing phenotype within the human bone marrow. Blood, 112(8), 3293-302 (2008)
80. C. E. Brown, R. P. Vishwanath, B. Aguilar, R. Starr, J. Najbauer, K. S. Aboody and M. C. Jensen: Tumor-derived chemokine MCP-1/CCL2 is sufficient for mediating tumor tropism of adoptively transferred T cells. J Immunol, 179(5), 3332-41 (2007)
81. A. Di Stasi, B. De Angelis, C. M. Rooney, L. Zhang, A. Mahendravada, A. E. Foster, H. E. Heslop, M. K. Brenner, G. Dotti and B. Savoldo: T lymphocytes coexpressing CCR4 and a chimeric antigen receptor targeting CD30 have improved homing and antitumor activity in a Hodgkin tumor model. Blood, 113(25), 6392-402 (2009)
82. R. A. Heyman, E. Borrelli, J. Lesley, D. Anderson, D. D. Richman, S. M. Baird, R. Hyman and R. M. Evans: Thymidine kinase obliteration: creation of transgenic mice with controlled immune deficiency. Proc Natl Acad Sci U S A, 86(8), 2698-702 (1989) (Pubitemid 19112610)
83. S. S. Yaghoubi, M. C. Jensen, N. Satyamurthy, S. Budhiraja, D. Paik, J. Czernin and S. S. Gambhir: Noninvasive detection of therapeutic cytolytic T cells with 18F-FHBG PET in a patient with glioma. Nat Clin Pract Oncol, 6(1), 53-8 (2009)
84. H. Singh, A. M. Najjar, S. Olivares, R. Nishii, U. Mukhopadhyay, M. Alauddin, P. R. Manuri, H. Huls, D. A. Lee, G. Dotti, C. Bollard, P. J. Simmons, E. J. Shpall, R. E. Champlin, J. G. Gelovani and L. J. Cooper: PET imaging of T cells derived from umbilical cord blood. Leukemia, 23(3), 620-2 (2009)
85. N. C. Munshi, R. Govindarajan, R. Drake, L. M. Ding, R. Iyer, R. Saylors, J. Kornbluth, S. Marcus, Y. Chiang, D. Ennist, L. Kwak, C. Reynolds, G. Tricot and B. Barlogie: Thymidine kinase (TK) gene-transduced human lymphocytes can be highly purified, remain fully functional, and are killed efficiently with ganciclovir. Blood, 89(4), 1334-40 (1997) (Pubitemid 27079997)
86. L. M. Serrano, T. Pfeiffer, S. Olivares, T. Numbenjapon, J. Bennitt, D. Kim, D. Smith, G. McNamara, Z. Al-Kadhimi, J. Rosenthal, S. J. Forman, M. C. Jensen and L. J. Cooper: Differentiation of naive cordblood T cells into CD19-specific cytolytic effectors for posttransplantation adoptive immunotherapy. Blood, 107(7), 2643-52 (2006)
87. V. Ponomarev, M. Doubrovin, A. Shavrin, I. Serganova, T. Beresten, L. Ageyeva, C. Cai, J. Balatoni, M. Alauddin and J. Gelovani: A human-derived reporter gene for noninvasive imaging in humans: mitochondrial thymidine kinase type 2. J Nucl Med, 48(5), 819-26 (2007) (Pubitemid 47604984)
88. C. J. Shu, D. O. Campbell, J. T. Lee, A. Q. Tran, J. C. Wengrod, O. N. Witte, M. E. Phelps, N. Satyamurthy, J. Czernin and C. G. Radu: Novel PET probes specific for deoxycytidine kinase. J Nucl Med, 51(7), 1092-8 (2010)
89. Y. Likar, J. Zurita, K. Dobrenkov, L. Shenker, S. Cai, A. Neschadim, J. A. Medin, M. Sadelain, H. Hricak and V. Ponomarev: A new pyrimidine-specific reporter gene: a mutated human deoxycytidine kinase suitable for PET during treatment with acycloguanosine-based cytotoxic drugs. J Nucl Med, 51(9), 1395-403 (2010)
90. C. H. June: Adoptive T cell therapy for cancer in the clinic. J Clin Invest, 117(6), 1466-76 (2007) (Pubitemid 46871329)
91. R. A. Morgan, M. E. Dudley, J. R. Wunderlich, M. S. Hughes, J. C. Yang, R. M. Sherry, R. E. Royal, S. L. Topalian, U. S. Kammula, N. P. Restifo, Z. Zheng, A. Nahvi, C. R. de Vries, L. J. Rogers-Freezer, S. A. Mavroukakis and S. A. Rosenberg: Cancer regression in patients after transfer of genetically engineered lymphocytes. Science, 314(5796), 126-9 (2006) (Pubitemid 44547756)
92. R. Brentjens, R. Yeh, Y. Bernal, I. Riviere and M. Sadelain: Treatment of chronic lymphocytic leukemia with genetically targeted autologous T cells: case report of an unforeseen adverse event in a phase I clinical trial. Mol Ther, 18(4), 666-8 (2010)
93. S. Hacein-Bey-Abina, A. Garrigue, G. P. Wang, J. Soulier, A. Lim, E. Morillon, E. Clappier, L. Caccavelli, E. Delabesse, K. Beldjord, V. Asnafi, E. MacIntyre, L. Dal Cortivo, I. Radford, N. Brousse, F. Sigaux, D. Moshous, J. Hauer, A. Borkhardt, B. H. Belohradsky, U. Wintergerst, M. C. Velez, L. Leiva, R. Sorensen, N. Wulffraat, S. Blanche, F. D. Bushman, A. Fischer and M. Cavazzana-Calvo: Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1. J Clin Invest, 118(9), 3132-42 (2008)
94. C. Baum, O. Kustikova, U. Modlich, Z. Li and B. Fehse: Mutagenesis and oncogenesis by chromosomal insertion of gene transfer vectors. Hum Gene Ther, 17(3), 253-63 (2006)
95. C. Bonini, M. Grez, C. Traversari, F. Ciceri, S. Marktel, G. Ferrari, M. Dinauer, M. Sadat, A. Aiuti, S. Deola, M. Radrizzani, A. Hagenbeek, J. Apperley, S. Ebeling, A. Martens, H. J. Kolb, M. Weber, F. Lotti, A. Grande, E. Weissinger, J. A. Bueren, M. Lamana, J. H. Falkenburg, M. H. Heemskerk, T. Austin, S. Kornblau, F. Marini, C. Benati, Z. Magnani, S. Cazzaniga, S. Toma, C. Gallo-Stampino, M. Introna, S. Slavin, P. D. Greenberg, M. Bregni, F. Mavilio and C. Bordignon: Safety of retroviral gene marking with a truncated NGF receptor. Nat Med, 9(4), 367-9 (2003) (Pubitemid 36460048)
96. Y. Zhao, Z. Zheng, C. J. Cohen, L. Gattinoni, D. C. Palmer, N. P. Restifo, S. A. Rosenberg and R. A. Morgan: High-efficiency transfection of primary human and mouse T lymphocytes using RNA electroporation. Mol Ther, 13(1), 151-9 (2006) (Pubitemid 41763493)
97. Y. Choi, C. Yuen, S. N. Maiti, S. Olivares, H. Gibbons, H. Huls, R. Raphael, T. C. Killian, D. J. Stark, D. A. Lee, H. Torikai, D. Monticello, S. S. Kelly, P. Kebriaei, R. E. Champlin, S. L. Biswal and L. J. Cooper: A high throughput microelectroporation device to introduce a chimeric antigen receptor to redirect the specificity of human T cells. Biomed Microdevices, 12(5), 855-63 (2011)
98. S. E. James, N. N. Orgun, T. F. Tedder, M. J. Shlomchik, M. C. Jensen, Y. Lin, P. D. Greenberg and O. W. Press: Antibody-mediated B-cell depletion before adoptive immunotherapy with T cells expressing CD20-specific chimeric T-cell receptors facilitates eradication of leukemia in immunocompetent mice. Blood, 114(27), 5454-63 (2009)
99. H. Singh, L. M. Serrano, T. Pfeiffer, S. Olivares, G. McNamara, D. D. Smith, Z. Al-Kadhimi, S. J. Forman, S. D. Gillies, M. C. Jensen, D. Colcher, A. Raubitschek and L. J. Cooper: Combining adoptive cellular and immunocytokine therapies to improve treatment of Blineage malignancy. Cancer Res, 67(6), 2872-80 (2007) (Pubitemid 46548978)